MT1-MMP (membrane type 1 matrix metalloproteinase, or MMP-14) is a key enzyme in molecular carcinogenesis, tumourcell growth, invasion and angiogenesis. Novel and potent MMP inhibitors with a mercaptosulphide zinc-binding functionality have been designed and synthesized, and tested against human MT1-MMP and other MMPs. Binding to the MT1-MMP active site was verified by the competitive-inhibition mechanism and stereochemical requirements. MT1-MMP preferred deep P1 substituents, such as homophenylalanine instead of phenylalanine. Novel inhibitors with a non-prime phthalimido substituent had K i values in the low-nanomolar range; the most potent of these inhibitors was tested and found to be stable against air-oxidation in calf serum for at least 2 days. To illustrate the molecular interactions of the inhibitor-enzyme complex, theoretical docking of the inhibitors into the active site of MT1-MMP and molecular minimization of the complex were performed. In addition to maintaining the substrate-specificity pocket (S1 site) van der Waals interactions, the P1 position side chain may be critical for the peptide-backbone hydrogen-bonding network. To test the inhibition of cellmediated substrate cleavage, two human cancer-cell culture models were used. Two of the most potent inhibitors tested reached the target enzyme and effectively inhibited activation of proMMP-2 by endogenous MT1-MMP produced by HT1080 human fibrosarcoma cells, and blocked fibronectin degradation by prostate cancer LNCaP cells stably transfected with MT1-MMP. These results provide a model for mercaptosulphide inhibitor binding to MT1-MMP that may aid in the design of more potent and selective inhibitors for MT1-MMP.
INTRODUCTION
MMPs (matrix metalloproteinases) are a family of zinc endopeptidases that play prominent roles during normal and pathological ECM (extracellular matrix) remodelling events, including cancer progression [1] . MT-MMPs (membrane type-MMPs) are a unique subset tethered to the cell membrane by a transmembrane domain or GPI (glycosylphosphatidylinositol) anchor [2] . The first identified MT-MMP, MT1-MMP, has been shown to play a central role in tumour-cell invasion and migration [3] [4] [5] [6] . It hydrolyses constituents of the ECM directly [7] [8] [9] and activates proMMP-2 (progelatinase A) efficiently; activated MMP-2 cleaves the basement membrane type IV collagen [10] [11] [12] [13] . Because MT1-MMP is highly localized at the leading edge of invading cancer cells and is a powerful proteolytic enzyme, it may be a good target for inhibition [14] .
Synthetic MMPIs (MMP inhibitors) have been in development for more than a decade. Potent MMPIs have three general requirements: a functional group capable of co-ordinating to the enzyme active site Zn(II), at least one functional group participating in hydrogen bonding with the enzyme, and one or more side chains participating in favourable van der Waals interactions, particularly at the substrate specificity pocket (S1 site) [15] . The most potent inhibitors reported have used a hydroxamic acid zinc-chelating group. Although this functionality affords good MMPI potency, many reports suggest the need for other functional groups owing to problems with oral bioavailability and toxicity [16] [17] [18] . Other MMPI functional groups include thiol, carboxylate, phosphinate and sulphodi-imine. Mercaptosulphide inhibitors that have been developed and characterized for several MMPs exhibit IC 50 and K i values comparable with those of well-known hydroxamic acids [19] [20] [21] [22] [23] . Mercaptosulphide peptidomimetic inhibitors are distinct from the hydroxamate peptidomimetics; they have different zincco-ordinating functionality, and the favoured stereochemistry at the P1 site is an unnatural D-amino-acid. In the present study, the inhibition characteristics of MT1-MMP with novel mercaptosulphide inhibitors were determined, and a model of the mercaptosulphide inhibitor complexed to MT1-MMP is proposed to provide a rational approach towards inhibitor design. Furthermore, the efficacy of potent new MMPIs was tested in live cells, using two different models of substrate cleavage mediated by human cancer cells expressing endogenous and transfected functional MT1-MMP respectively.
EXPERIMENTAL

Materials
The fluorescence-quenched peptide substrate, Mca [(7-methoxycoumarin-4-yl)acetyl]-Pro-Leu-Gly-Leu-Dpa [N-3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl]-Ala-Arg-NH 2 , was purchased Abbreviations used: cdMT1-MMP, catalytic domain of membrane type 1 matrix metalloproteinase; ConA, concanavalin A; Dpa, N-3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl; DTNB, 5,5 -dithiobis-(2-nitrobenzoic acid); ECM, extracellular matrix; FN, fibronectin; GFP, green fluorescent protein; GPI, glycosylphosphatidylinositol; Mca, (7-methoxycoumarin-4-yl)acetyl-; MMP, matrix metalloproteinase; MMPI, MMP inhibitor; MT1-MMP, membrane type 1 MMP; MT1-GFP, MT1-MMP complexed to GFP; proMMP-2, progelatinase A; TCEP, tris-(2-carboxyethyl)phosphine; TIMP-2, tissue inhibitor of metalloproteinases-2. 1 To whom correspondence should be addressed (email qxsang@chem.fsu.edu).
from Bachem. The mercaptosulphide inhibitors were synthesized and characterized as described previously [19, 21, 23, 24] . The recombinant cdMT1-MMP (catalytic domain of MT1-MMP) was provided by Professor Harald Tschesche (Bielefeld University, Eastern Westphalia, Germany) [22, 25] . MMP-1, -2, -3, -7 and -9 were described previously [21] . FITC was purchased from Pierce Biotechnology, and human FN (fibronectin) was from Invitrogen. All standard chemicals were purchased from Fisher Scientific with the exception of Ellman's reagent/DTNB [5,5 -dithiobis-(2-nitrobenzoic acid)] and ConA (concanavalin A), which were from Sigma, and TCEP [tris-(2-carboxyethyl)-phosphine], which was from Calbiochem. Human fibrosarcoma cell line HT1080 and human prostate cancer cell line LNCaP were purchased from ATCC (Manassas, VA, U.S.A.) and were maintained in Dulbecco's modified Eagle's medium (Invitrogen).
Inhibitor-concentration determination
The reduced mercaptosulphide inhibitor concentration was determined with DTNB [20, 26] . Absorbance was measured with a Shimadzu UV-260 UV-visible spectrophotometer with a 2 nm slit-width. Alternatively, for inhibitors with a phthalimido substituent, the total concentration of inhibitor was determined by absorbance at 219 nm. The molar absorption coefficient, ε 219 , was determined for a standard, N-phthaloyl-L-phenylalanine, by measuring absorbance for concentrations up to 40 µM of four separate stock solutions. The ε 219 was determined to be (3.30
Enzyme kinetics
Kinetic assays were performed with the peptide substrate McaPro-Leu-Gly-Leu-Dpa-Ala-Arg-NH 2 (1 µM) as described previously [27, 28] . The assays were performed in 50 mM Hepes buffer, pH 7.5, with 10 mM CaCl 2 , 0.2 M NaCl and 0.05 % (w/v) Brij-35 (polyoxyethylene dodecyl ether) at 25
• C. Active cdMT1-MMP concentrations were determined by titration with standardized preparations of recombinant TIMP-2 (tissue inhibitor of metalloproteinases-2) [22] . For the inhibition assays, the inhibitors were incubated with enzyme for 15-30 min before adding substrate, to ensure equilibrium conditions. For those inhibitors with a phthalimido substituent, 1 mM TCEP (a reducing agent) was included to ensure complete reduction of the inhibitor to the free thiol. No effect on enzyme activity was noted for concentrations of TCEP up to 1 mM. The inhibitor dissociation constant, K i , was determined as described previously [29] using the Morrison equation [30] : 
Inhibitor stability
The stability of the thiol was determined using the inhibition assay to quantify the concentration of active inhibitor. Selected inhibitors were incubated in calf serum at 37 • C. Aliquots were removed periodically, diluted with the assay buffer (described above) to 25 % serum, and the inhibition was tested against cdMT1-MMP. Control assays containing the same amounts of serum with no inhibitor were performed to obtain relative rates.
Modelling studies
The co-ordinates from the X-ray crystal structure of the cdMT1-MMP-TIMP-2 complex were downloaded from the Brookhaven Protein Data Bank (accession number 1BUV) [31] . MacroModel version 7.0 was used to remove the TIMP-2 molecule, and the inhibitors were theoretically docked into the active site of cdMT1-MMP by the following procedure: the MMP-1-hydroxamic acid inhibitor complex (PDB accession number 1HFC) [32] was modified at the inhibitor zinc-co-ordinating group to a mercaptosulphide functionality; the modified structure was energy-minimized according to procedures described below; the imidazolyl nitrogen atoms co-ordinated to zinc of the minimized structure were superimposed with those of cdMT1-MMP; and MMP-1 was deleted to leave the inhibitor bound in the cdMT1-MMP active site. Both sulphurs of the mercaptosulphide functionality were co-ordinated to zinc with zero-order bonds. The rationale for this zinc chelation was based primarily on earlier studies of the inhibition of MMP-1, -2, -3, -7, -8 and -9 with a mercaptosulphide inhibitor modified with an oxygen in place of the sulphide, which significantly reduced inhibitor potency. The mercaptosulphide inhibitor had IC 50 Energy minimizations of the inhibitor and all enzyme residues within 7 Å (1 Å = 0.1 nm) were performed with MacroModel version 7.0. Briefly, the AMBER force field [33, 34] , modified to include parameters for Zn and Ca ( [35] [36] [37] ; M. A. Schwartz, Y. Jin, D. R. Hurst and Q.-X. Sang, unpublished work), was used with the PRCG (Polak-Ribiere conjugate gradient) method with a 0.05 gradient threshold in a GB/SA (generalized Born solvent/accessible surface area) continuum water solvent. A global minimization of the cdMT1-MMP-inhibitor complex was carried out using the MCMM (Monte Carlo multiple minimum) method (1000 steps), in which the inhibitor torsion angles at all relevant bonds were randomly varied and then minimized.
Gelatin substrate zymography and densitometry analyses of the bands
The procedures were reported in our previous papers [38, 39] . In brief, HT1080 cells were pre-treated with different doses of the novel MMPIs in serum-free medium at 37
• C for 1 h, followed by stimulation with ConA (20 µg/ml) at 37
• C for 18 h. The spent conditioned media were collected and examined by gelatin zymography. The effect of the novel MMPI on proMMP-2 activation by MT1-MMP was documented by densitometry analysis for 62 kDa fully active MMP-2 using AlphaImager TM 2200 with AlphaEaseFC software (AlphaInnotech).
FITC-FN degradation assay
To observe cell-mediated protein-substrate degradation and cell migration, FN was conjugated to FITC in borate-buffered saline (pH 10) for 30 min at room temperature (approx. 23
• C). After extensive dialysis against PBS, FITC-labelled FN was coated on to glass coverslips by incubation with glutaraldehyde-cross-linked gelatin for 1 h at room temperature [39] . Human prostate cancer
Table 1 Inhibition constants for inhibition of MT1-MMP and other MMPs by mercaptosulphide inhibitors
Stereochemistry (*) for the C α to SH is always listed first. Data were reported in a [22] and b [21] . iBu, isobutyl; PhMe, phenylmethyl; PhEt, phenethyl; PhtN, phthalimido; PhtNMe, phthalimidomethyl; PhtNBu, phthalimidobutyl; PhtNPr, phthalimidopropyl; PhtNPe, phthalimidopentyl; PhtNEt, phthalimidoethyl; PhtNEtNH, phthalimidoethylimino; PMP, paramethoxyphenyl. cell line LNCaP cells stably transfected with MT1-GFP (MT1-MMP-green fluorescent protein) cDNA construct were generated as described previously [39] . LNCaP cells expressing the MT1-GFP chimaera were plated onto FITC-FN coverslips and incubated with vehicle control (DMSO), TIMP-2, YHJ-132 or YHJ-294-2 at different concentrations in serum-free medium at 37
• C for 18 h. The cells were then fixed with 4 % (w/v) paraformaldehyde in PBS and examined under a fluorescent microscope (Olympus, IX-70). The substrate degradation was demonstrated by loss of fluorescence of FITC-labelled substrate and cell migration was determined by observing the tracks of digested substrate on the same slide. MT1-GFP-expressing cells digested FN and migrated over digested substrate. The dark lines on the green FITC-FN background indicate substrate degradation and cell migration. The cells are also green because of the GFP expression together with MT1-MMP.
RESULTS
Mechanism of interaction
The inhibitors (Table 1) were designed with a zinc-co-ordinating functionality and would be predicted to bind in the active site groove of MMPs based on structures of similar hydroxamate inhibitors complexed with MMP-1. However, detailed inhibition mechanisms have not been determined experimentally, and alternative modes of inhibition must be considered. To verify a competitive mechanism of inhibition, a prototypical inhibitor, MAG-182, was assayed with cdMT1-MMP at several substrate concentrations. A linear form of the Morrison equation derived by Henderson [40] (eqn 3) was applied: 
, which is also a thiol compound, was used as a negative control and found to have a K i value of 4 mM. Therefore the mercaptosulphide inhibitors are interacting exclusively at the enzyme active site. The competitive mechanism of inhibition does not distinguish between primed and unprimed binding. Members of the MMP family are known to have either a deep or a shallow S1 pocket that is easily probed by modifying the P1 substituent. Shallowpocket MMPs, MMP-1 and -7, have K i values that are an order of magnitude higher compared with deep-pocket MMPs, such as MT1-MMP, for inhibitors with an extended-chain P1 substituent. The inhibition by MAG-182 and YHJ-73 is compared with MMP-1 and -7 and MT1-MMP in Table 1 . Respective K i values for MMP-1 are 49 nM and 12 µM; for MMP-7, 40 nM and 1 µM; and for MT1-MMP, 24 nM and 16 nM [21] . The significant decrease in inhibition potency with a homophenylalanine side chain, compared with leucine, against MMP-1 and -7 demonstrates that the P1 substituent is interacting at the S1 pocket.
To ensure that the binding interactions are specific, the stereochemical dependence of inhibition was probed. Variation in the stereochemistry of the inhibitor near the zinc-co-ordinating functionality and at the P1 side chain led to variation in inhibition. The C α to SH favours the absolute S configuration (compare MAG-133 with MAG-128), and the derivatives containing a cyclopentyl or pyrrolidinyl ring significantly favour the S,R configuration (C α ,C β to SH respectively; compare MAG-182 with MAG-181, YHJ-73 with YHJ-72, and YHJ-294-2 with YHJ-294-1). The stereochemical requirements at the P1 site favour the absolute R configuration corresponding to the unnatural D-amino-acid Table 1 .
derivative (compare MAG-42 with MAG-58). These results confirm that stereochemistry is important for inhibitor potency and provide additional support for the inhibitor interacting specifically and exclusively at the active site of the enzyme.
Probing the non-prime site
From the crystal structure of cdMT1-MMP, the non-prime site does not have well-defined pockets comparable with S1 . However, it was found that a phthalimido substituent (Figure 2 ) added to the C α to SH of MAG-42 (MAG-292) increased the potency by a factor of five (Table 1) . Compared with a methyl group (MAG-133), the potency is increased by a factor of four. To probe the possibility of a specific interaction with cdMT1-MMP, the tether length attaching the phthalimido substituent was increased by two carbons (MAG-254). No change was noted in the K i value, suggesting that the increase in potency is because of non-specific hydrophobic interactions.
A new series of mercaptosulphide inhibitors that incorporate a pyrrolidine ring at the zinc-co-ordinating functionality was designed to increase water-solubility and possibly provide structural features that would allow for greater selectivity of inhibition (Table 1 , compound 3) [21, 23] . These derivatives displayed identical stereochemical requirements for potency with the previously designed mercaptosulphides (compounds 1 and 2). A phthalimido substituent was also added, with varying tether lengths, to the N-acetyl of these compounds, with no change in potency (YHJ-265, -97 and -44). However, a 10-fold increase in K i was noted for the N-phthalimidomethylacetyl (YHJ-96). This suggests that YHJ-96 is sterically hindered by the short attachment of the phthalimido substituent, or possibly that π-π interactions between the phthalimido and an aromatic residue of the enzyme affect inhibitor binding. Incorporating a urea group (YHJ-132, -133, -223 and -224) did not affect the K i , although the water-solubility would be significantly increased.
The mercaptosulphide inhibitors may be readily air-oxidized in buffer and typically lose their effectiveness as MMPIs over time. Stability experiments with the non-cyclic mercaptosulphide, MAG-42, in buffer showed complete loss of inhibitor activity within 45 min at 25
• C. Incorporation of the cyclopentyl ring at the mercaptosulphide functionality, MAG-182, increased inhibitor stability by approx. 6 h. Pyrrolidinyl derivatives of these inhibitors have improved water-solubility and may be candidates for in vitro cell and in vivo animal studies (M. A. Schwartz, Y. Jin, D. R. Hurst and Q.-X. Sang, unpublished work). Moreover, the phthalimidoethylurea derivative, YHJ-132, which is the most potent of these inhibitors towards cdMT1-MMP, was stable for at least 2 days in calf serum at 37
• C (M. A. Schwartz, Y. Jin, D. R. Hurst and Q.-X. Sang, unpublished work). The simple urea derivative, YHJ-294-2, was stable for approx. 4-6 h. MAG-42 and MAG-182 were tested in calf serum and were found to have stability similar to that found in the buffer experiments.
Proposed model
These mercaptosulphide inhibitors appear to be structurally similar to some well-characterized hydroxamate peptidomimetic MMPIs and might be predicted to interact correspondingly; however, the mercaptosulphides are distinct from the hydroxamate peptidomimetics with regard to the zinc-co-ordinating functionality and the favoured unnatural D-amino-acid stereochemistry at the P1 site. Molecular modelling was employed for structural analysis of the binding of the mercaptosulphide inhibitors into the cdMT1-MMP active site. The enzyme-inhibitor complexes were globally minimized so that interactions important for inhibitor potency could be identified. Rational explanations for the disparity between K i values of structurally similar inhibitors were sought and identified.
The three general requirements for MMPI potency are achieved with mercaptosulphide inhibitors: a zinc-binding functionality, multiple hydrogen bonds and favourable van der Waals interactions with the S1 pocket. The cdMT1-MMP complexed with the inhibitor MAG-182 is illustrated in Figure 3 . The inhibitor interacts with the primed side of the enzyme active site, with the P1 leucine side chain oriented with one terminal methyl in line with the S1 pocket. Four hydrogen bonds between the peptide backbone of the mercaptosulphide inhibitors and the enzyme active site were identified. The P1 carbonyl hydrogen bonds with the NH of Leu 199 , the P2 NH with the carbonyl of Pro 259 , the P2 carbonyl with the NH of Tyr 261 and the terminal NH with the carbonyl of Gly 197 . Importantly, the Phe 198 between the hydrogenbonding residues Gly 197 and Leu 199 is co-ordinated to a structurally important calcium ion [31] . This severely limits the flexibility of these residues.
Substitution at the P1 site demonstrated the largest difference in K i values. Even though a phenylalanine side chain would be predicted to show potency similar to that of a leucine side chain based on previous substrate studies [41] , comparison of the inhibition by two such inhibitors (MAG-42 and -148) actually showed more than a 350-fold difference in K i . These two inhibitors complexed with cdMT1-MMP were superimposed ( Figure 4A ). The inhibitors overlay quite well, with the exception of the P1 carbonyl, which is a key hydrogen-bonding group with the NH of Leu 199 . The N to O distance is 3.2 and 3.6 Å for MAG-42 and -148 respectively. The disruption of this hydrogen bond is owing to the restricted orientation of the phenylalanine side chain by the well-defined S1 pocket, along with the restricted flexibility of Leu 199 due to co-ordination of the adjacent residue, Phe 198 , to a structural calcium ion. The respective inhibitor with a homophenylalanine side chain superimposed with MAG-42 maintains all of the necessary hydrogen-bonding interactions ( Figure 4B ). The C 1 phenyl ring atom is located in the same position as the terminal methyl carbon that is pointing in the direction of the S1 pocket. Therefore there is no distortion of the inhibitor backbone, and all necessary interactions are maintained. The distortion of the backbone in MAG-148 is a result of the steric restriction of the phenyl ring in the S1 pocket. Disruption of one hydrogen bond, with all other interactions being the same, could account for a free energy change of the order of 8-21 kJ/mol. The free energy is related to K i by eqn (4):
and a 10-fold difference in K i corresponds to a free energy change of 5.69 kJ/mol, 100-fold corresponds to 11.38 kJ/mol, and 1000-fold corresponds to 17.07 kJ/mol. A reasonable explanation for the 350-fold difference in K i between MAG-42 and -148 is disruption of a single hydrogen bond. This is the first report to provide a rationale for the large disparity between these side chains in terms of either substrate specificity or inhibition studies. The 10-fold difference in K i for YHJ-96 and -97 was also very intriguing. These inhibitors differ only in the tether length for the attachment of the phthalimido substituent at the non-prime site. Modelling of YHJ-97 showed an edge-to-face aromatic-aromatic interaction between the phthalimido ring and Phe 260 that was not identified for YHJ-96 ( Figure 5 ). The YHJ-97 phthalimido ring is oriented towards the centre of the phenyl ring of Phe 260 , with a distance of 5.5 Å between the two phenyl ring centroids. The preferential distance between phenyl ring centroids is 4.5-7 Å for this type of interaction and may contribute up to 8.4 kJ/mol of free energy [42] , which correlates well with the 10-fold difference in K i between these inhibitors.
Inhibition by MMPIs of MT1-MMP-mediated substrate cleavage in cells
Two potent broad-spectrum and relatively stable novel MMPIs, YHJ-132 and YHJ-294-2, have been tested in two different human cancer-cell culture systems to examine their inhibition quickly converted into the 62 kDa active form; at 100 nM of each of these two inhibitors, this conversion was effectively blocked, but the inhibition of the conversion of the 72 kDa zymogen into the 64 kDa species was incomplete ( Figure 6 ). From these results, it appears that the 64 kDa form is 'stabilized' by these inhibitors, indicating that these two inhibitors are less effective on MT1-MMP than on MMP-2, which is consistent with the enzyme-inhibition parameters, demonstrating that these two inhibitors are slightly less potent against MT1-MMP than MMP-2 ( Table 1) . The K i values for YHJ-132, YHJ-294-2 and some other mercaptosulphide inhibitors against MMP-1, 2, -3, -7, -9 and MT1-MMP are shown in Table 1 . The second model utilizes the human prostate cancer cell line LNCaP cells expressing stably transfected MT1-GFP chimaera. These cells were plated on to FITC-FN glass coverslips. YHJ-132 and YHJ-294-2 partially or completely inhibited MT1-MMP-and perhaps other MMP-induced substrate degradation at 5 µM and 10 µM, but were much less effective in blocking cell migration (Figure 7) . TIMP-2, at 1 µM, completely inhibited cellmediated substrate cleavage and partially impeded cell migration. These results are consistent with our previous report that MMPIs did not effectively stop cell migration, owing to MMPindependent migration mechanisms such as phagocytosismediated cell movement and migration [39] . These data demonstrate that these novel synthetic inhibitors are able to reach MT1-MMP and other MMPs produced by live cells and block their substrate digestion.
DISCUSSION
In the present study, the inhibition profile, mechanisms and requirements for potency of mercaptosulphide inhibitors against the target enzyme, cdMT1-MMP, have been investigated. Synthetic MMPIs have been developed and characterized extensively with collagenase 1 and 2 (MMP-1 and -8), gelatinase A and B (MMP-2 and -9), stromelysin 1 (MMP-3), and matrilysin (MMP-7), but few inhibition studies have included MT1-MMP. The most potent inhibitors developed by other researchers contain a hydroxamic acid zinc-chelating group, and these compounds have been the lead agents for clinical trials. The results of some clinical trials have been disappointing for many reasons; for example, the trial design may not have been optimal and the hydroxamate inhibitors may not be specific [43] [44] [45] [46] [47] . There is an urgent need for developing MMPIs with novel zinc-binding groups [48] [49] [50] . Mercaptosulphide inhibitors have been developed and characterized for many MMPs and exhibit IC 50 and K i values approaching those of well-characterized hydroxamates [19] [20] [21] [22] [23] . The detailed mechanisms of interaction of these inhibitors with a MMP have not been previously elucidated.
The mercaptosulphide inhibitors were demonstrated to bind reversibly and competitively to MMPs. In agreement with other MMP family members, there is strong stereoselectivity at the P1 and zinc-binding groups. This observation correlates with structural studies that indicate that MMPs have a highly conserved active site [51] . Stereochemistry at the P1 site favours the absolute R configuration corresponding to the unnatural D-amino-acid derivative. Around the mercaptosulphide zinc-co-ordinating functionality, the S,R stereochemistry is favoured (C α ,C β to thiol). The non-prime site was probed with a phthalimido substituent. The inhibition potency of inhibitors containing this substituent was comparable with, and in some cases improved upon, that of similar inhibitors without the non-prime phthalimido. An exception was noted with YHJ-96, which was 10-fold less potent than YHJ-97. These inhibitors differ only in the tether length for the attachment of the phthalimido (methyl and propyl respectively). The S1 pocket is the most well-defined pocket and is deep in MT1-MMP compared with other MMPs. This pocket may simply accommodate long hydrophobic groups at the inhibitor P1 site and therefore a phenylalanine side-chain inhibitor should be approximately equal in potency when compared with leucine. However, MAG-148, which contains a P1 phenylalanine side chain, was found to be less potent (more than 350-fold) than the corresponding inhibitor MAG-42 with a leucine side chain. This result could not be predicted from the descriptions posted in the literature regarding inhibitor binding. It was therefore necessary to evaluate the experimental results with molecular modelling to propose rational explanations for the requirements of inhibitor potency.
The overall inhibition by the mercaptosulphide compounds of cdMT1-MMP follows the general requirements of other MMP-family members, with the exception of YHJ-96. Although the non-prime site is not of particular importance for selectivity, the 10-fold difference in K i between YHJ-96 and -97 is interesting. An aromatic-aromatic interaction was identified between YHJ-97 and Phe 260 that was not seen with YHJ-96. This would explain the 10-fold difference in potency against cdMT1-MMP. MMP-3 was the only other MMP that showed this behaviour. It is not clear whether MMP-3 interacts with these inhibitors in a similar fashion; however, Cohen and colleagues recently reported π-π stacking interactions at the non-prime site for the inhibitor futoenone complexed with MMP-3 [52] . This inhibitor is selective for MMP-3 over other MMPs owing to a unique tyrosine residue. The cdMT1-MMP Phe 260 appears to be located at the S2 site. Therefore the phthalimido substituent in YHJ-97 may be interacting at the S2 site and not in the non-prime site as would have been predicted. Although YHJ-97 is not selective for cdMT1-MMP compared with other MMPs, the 10-fold preference of cdMT1-MMP for YHJ-97 over YHJ-96 could be explained rationally with modelling. Extension of the tether length to five carbons, as in YHJ-44, did not affect inhibitor potency compared with YHJ-97.
The S1 pocket has been the most-characterized site in MMPs, especially with regards to inhibition studies. Although MT1-MMP is known to have a deep S1 pocket, the phenylalanine side-chain inhibitor, MAG-148, was more than 350-fold less potent compared with the leucine side-chain inhibitor, MAG-42. Four hydrogen bonds between the peptide backbone of mercaptosulphide inhibitors and the enzyme active site appear to be necessary for inhibition potency. Disruption of one of these bonds, with all other interactions being the same as predicated, as in the case of MAG-148, could account for a free energy change of the order of 8-21 kJ/mol. The cdMT1-MMP active site is rigid at the Leu 199 hydrogen-bonding site owing to the structural calcium metal that is co-ordinated to the adjacent residue, Phe 198 . This calcium-binding site is highly conserved among the MMPs and may be the reason why MAG-148 is not favoured in any of the deep-pocket MMPs tested. The present paper is the first report to provide a rationale for the large disparity between these side chains in terms of either substrate specificity or inhibition potency.
A new series of inhibitors incorporating a pyrrolidinyl ring at the zinc-binding functionality (Table 1 , compound 3) has been developed recently [21, 23] . These compounds have increased water-solubility, while maintaining inhibitor potency. The stereochemical requirements of these inhibitors are the same as for the previously designed inhibitors (Table 1, compounds 1 and 2) and demonstrate binding in the same orientation. The increased watersolubility may correspond to an improved oral bioavailability that must be considered for future drug design. Therefore these compounds may be ideal candidates for future in vivo cancer-cell invasion and metastasis studies.
The prominent roles of MMPs in diseases have led to aggressive targeting of these enzymes by pharmaceutical companies. Despite all the advancements in MMPI research, and particularly with hydroxamic acids, clinical trials have been disappointing. Recent papers suggest the need for specific targeting of MT1-MMP in cancer invasion [5, 6] . To increase our understanding of MMPIs, and particularly mercaptosulphide inhibitors, we have characterized them with a potential target, MT1-MMP, in enzymeinhibition kinetic and mechanistic studies. Moreover, we have demonstrated that these inhibitors have reached their target enzyme on the cell surface and blocked the substrate cleavage by MT1-MMP in two different human cancer-cell culture systems, with functional endogenous and exogenous MT1-MMP expression respectively. Owing to the exceptionally significant roles that MT1-MMP plays, not only in cancer-cell invasion and growth [1] [2] [3] [4] [5] [6] [7] [8] , but also in conferring tumorigenicity on nonmalignant epithelial cells [53, 54] , it is essential to make efforts to develop novel potent and selective inhibitors to target MT1-MMP. Our studies might identify enzyme-inhibitor interactions that assist the rational design of new generations of compounds with increased potency, selectivity, stability and water-solubility.
